# A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock

> **NCT04963920** · NA · SUSPENDED · sponsor: **CytoSorbents Europe GmbH** · enrollment: 260 (estimated)

## Conditions studied

- Septic Shock

## Interventions

- **DEVICE:** Cytosorb® 300 ml

## Key facts

- **NCT ID:** NCT04963920
- **Lead sponsor:** CytoSorbents Europe GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-01-30
- **Primary completion:** 2027-02
- **Final completion:** 2027-05
- **Target enrollment:** 260 (ESTIMATED)
- **Why stopped:** Recruitment for the study is currently on hold to allow for a protocol amendment. This revision aims to align the study design with changes in clinical practice since the trial's initiation.
- **Last updated:** 2025-08-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04963920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04963920, "A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04963920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*